The possibilities of using combination therapy in patients with dyscirculatory encephalopathy

Abstract.The article presents the results of a clinical study on the efficiency and tolerability of the combined use of drugs Neurocytin and Latren, solutions in comparison with the drug Neurocytin, solution, produced by Yuria Pharm Ltd. in patients with stage II arterial hypertension (AH) and atherosclerosis.
Studies were conducted in 92 patients of both sexes, aged from 52 to 76 years old. The patients were divided into 3 groups: 30 patients received Neurocytin 100 ml/day and Latren 200 ml/day intravenosus (main group), 30 patients received Neurocytin 100 ml/day (comparison group). The control group consisted of 32 patients with DE II stage, who received only basic therapy. The course of drug use was 10 days.
The efficiency and safety of drugs under study were evaluated on the basis of clinical, neurological, psychodiagnostical, laboratory and statistical methods.
The results of the study made it possible to conclude that the combined use of the drugs Neurocytin and Latren has a more expressed (compared to Neurocytin) therapeutic effects on the clinical and neurological symptoms, cognitive functions, asthenic symptoms. The course of treatment with two drugs did not reveal any side effects or intolerance in patients.
Keywords: dyscirculatory encephalopathy, treatment, combination therapy, cognitive impairment.